系统性综述干细胞来源的生物材料采集的供者健康风险

Systematic Review of the Donors’ Health Risks of Biomaterial Collection to Stem Cell Providers

通过检索国内外6个文献数据库以获取发表于2010年1月~2020年7月研究相关的文献,并对干细胞来源的生物材料采集的供者健康风险进行了系统性综述。50篇相关文献分析显示,在许多情况下,生物材料采集可使供者承受健康风险,包括麻醉、粒细胞集落刺激因子或促排卵药物使用、中心静脉导管放置、穿刺等带来的风险。此外,生物材料采集还可影响供者的心理健康。根据上述发现,建议干细胞来源的生物材料采集需要严格的伦理管控,以保障生物材料供者的健康权益。

Six literature databases in China and abroad were searched to obtain relevant literatures published from January 2010 to July 2020, and a systematic review was conducted to analyze the health risks of biomaterial collection to the persons who provided biomaterial as source of stem cells. After analyzing 50 literatures on the health risks of biomaterial providers, the study found biomaterial collection may leave the biomaterial providers potential health risks in many cases. Potential risks were caused by anaesthesia, granulocyte colony stimulating factor, ovulation induction drugs, placement of central venous catheter, bone marrow aspirations and others. In addition, biomaterial collection may also affect mental health of the providers. According to the study findings, the authors suggested that biomaterial collection as sources of stem cells should be strictly and ethically controlled to ensure the health right of biomaterial providers.